NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Clinical trial NCT06345300 · UNKNOWN
Trial details
- NCT number
- NCT06345300
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-10
- Primary completion
- 2024-12-12
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.